Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiana Bettoni

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
FEBS Letters|November 6, 2004
Allele-specific transcript isoforms in humanVictoria Nembaware, Kenneth H Wolfe, Fabiana Bettoni, et al.
Frontiers in Oncology|April 11, 2019
Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal CancerFranciele H Knebel, Fabiana Bettoni, Leonardo G da Fonseca, et al.
Health Security|August 12, 2022
Seroprevalence of SARS-CoV-2 in Emergency Department Healthcare Workers at Sírio-Libanês Hospital, BrazilRicardo Madureira, Silvia Aparecida Ferreira, Magali Aldrin Lopes Marion, et al.
Experimental and Molecular Pathology|November 28, 2017
A straightforward assay to evaluate DNA integrity and optimize next-generation sequencing for clinical diagnosis in oncologyFabiana Bettoni, Fernanda Christtanini Koyama, Paola de Avelar Carpinetti, et al.
International Journal of Cancer|January 25, 2008
Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrenceRaphael B Parmigiani, Fabiana Bettoni, Daniela M Grosso, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLCFranciele H Knebel, Fabiana Bettoni, Andrea K Shimada, et al.
The Journal of Pathology|November 24, 2021
Monoallelic deleterious MUTYH germline variants as a driver for tumorigenesisRodrigo Araujo Sequeira Barreiro, Jorge Sabbaga, Benedito M Rossi, et al.
Frontiers in Cellular and Infection Microbiology|May 9, 2022
Choice of 16S Ribosomal RNA Primers Impacts Male Urinary Microbiota ProfilingVitor Heidrich, Lilian T Inoue, Paula F Asprino, et al.
JCO Precision Oncology|August 31, 2022
Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD-L1 Expression FindingsMarcello M Queiroz, Rodrigo R Munhoz, Cibele Masotti, et al.
Oncotarget|October 10, 2015
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiationPaola Carpinetti, Elisa Donnard, Fabiana Bettoni, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
FEBS Letters|November 6, 2004
Allele-specific transcript isoforms in humanVictoria Nembaware, Kenneth H Wolfe, Fabiana Bettoni, et al.
Frontiers in Oncology|April 11, 2019
Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal CancerFranciele H Knebel, Fabiana Bettoni, Leonardo G da Fonseca, et al.
Health Security|August 12, 2022
Seroprevalence of SARS-CoV-2 in Emergency Department Healthcare Workers at Sírio-Libanês Hospital, BrazilRicardo Madureira, Silvia Aparecida Ferreira, Magali Aldrin Lopes Marion, et al.
Experimental and Molecular Pathology|November 28, 2017
A straightforward assay to evaluate DNA integrity and optimize next-generation sequencing for clinical diagnosis in oncologyFabiana Bettoni, Fernanda Christtanini Koyama, Paola de Avelar Carpinetti, et al.
International Journal of Cancer|January 25, 2008
Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrenceRaphael B Parmigiani, Fabiana Bettoni, Daniela M Grosso, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLCFranciele H Knebel, Fabiana Bettoni, Andrea K Shimada, et al.
The Journal of Pathology|November 24, 2021
Monoallelic deleterious MUTYH germline variants as a driver for tumorigenesisRodrigo Araujo Sequeira Barreiro, Jorge Sabbaga, Benedito M Rossi, et al.
Frontiers in Cellular and Infection Microbiology|May 9, 2022
Choice of 16S Ribosomal RNA Primers Impacts Male Urinary Microbiota ProfilingVitor Heidrich, Lilian T Inoue, Paula F Asprino, et al.
JCO Precision Oncology|August 31, 2022
Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD-L1 Expression FindingsMarcello M Queiroz, Rodrigo R Munhoz, Cibele Masotti, et al.
Oncotarget|October 10, 2015
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiationPaola Carpinetti, Elisa Donnard, Fabiana Bettoni, et al.
Pageof 3